

**Supplementary Table 5.** Logistic regression analysis to determine variables associated with good responders to SGLT2 inhibitors in the add-on and switch group

Variable	Add-on			Switch		
	Odds ratio	95% CI	P value	Odds ratio	95% CI	P value
<b>Univariate</b>						
Age, yr	0.97	0.95–1.00	0.049	0.99	0.97–1.02	0.451
Female sex	1.58	0.89–2.80	0.118	0.83	0.44–1.57	0.557
BMI, kg/m <sup>2</sup>	1.03	0.95–1.11	0.451	1.05	0.98–1.13	0.154
Duration of diabetes, yr	0.97	0.93–1.00	0.036	0.98	0.94–1.03	0.386
Subtype of SGLT2 inhibitor (dapagliflozin)	0.86	0.38–1.94	0.711	0.69	0.35–1.38	0.692
Baseline HbA1c, %	1.53	1.16–2.02	0.003	1.44	1.12–1.84	0.004
Baseline FPG, mg/dL	1.01	1.00–1.01	0.065	1.00	1.00–1.01	0.802
Baseline eGFR, mL/min/1.73 m <sup>2</sup>	1.01	0.99–1.02	0.267	1.01	0.99–1.02	0.410
No insulin therapy	2.11	1.19–3.73	0.011	1.18	0.61–2.28	0.626
<b>Multivariate</b>						
Age, yr	0.99	0.96–1.02	0.439	1.00	0.97–1.03	0.921
Duration of diabetes, yr	0.97	0.92–1.03	0.162	0.99	0.93–1.04	0.577
Baseline HbA1c, %	2.09	1.48–2.94	<0.001	1.66	1.23–2.24	0.001
No insulin therapy	2.64	1.20–5.82	0.016	2.12	0.89–5.06	0.089

SGLT2, sodium-glucose cotransporter-2; CI, confidence interval; BMI, body mass index; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate.